Foreword
Crohn’s disease is a growing problem, and yet to be fully understood. Janssen has been building on experience within dermatology and rheumatology to extend research in immunology. Having already brought the first anti-TNF to market back in 1998, Janssen hopes to continue leading the way through the development of new, tailored therapeutic options – so patients can start a new chapter in their lives.
Read on for the full story.
